Algorae Pharmaceuticals Limited
1AI
Rang in aandelen
#30933
Algorae Pharmaceuticals Limited, a company established in 1987 and based in... Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Aandeelprijs
$0.00705285
Marktkapitalisatie
$14.30M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-30.71%
Land
AU
Handel Algorae Pharmaceuticals Limited (1AI)
Categorie
Healthcare
Marktkapitalisatie van Algorae Pharmaceuticals Limited(1AI)
Marktkapitalisatie: $14.30M
Vanaf October 2026 heeft Algorae Pharmaceuticals Limited een marktkapitalisatie van $14.30M. Dit maakt Algorae Pharmaceuticals Limited volgens onze gegevens het 30933rd meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Algorae Pharmaceuticals Limited van 2004 tot 2026
1AI vergeleken met de top 5 populairste stocks
